At Serpenta, we are pioneering a new generation of surgical robots to revolutionise endoluminal surgery in the lower gastrointestinal (GI) tract. Our initial focus is on transforming the treatment of early-stage colorectal cancer by reducing risk, lowering costs, and improving patient outcomes.

Our flagship product, currently under development, is a miniature dual-arm snake robot designed to perform endoluminal surgery anywhere in the colon. Each arm is based on a patented soft robotic design actuated by pressurised fluids, originally developed by our co-founder during his doctorate at Imperial College London. We are now industrialising this technology into a fully integrated surgical system that enables high-precision, dexterous procedures, such as Endoscopic Submucosal Dissection (ESD) and Endoscopic Mucosal Resection (EMR), anywhere in the colon. With this breakthrough, Serpenta aims to make advanced endoluminal procedures widely accessible.

Beyond our lead product, our team brings deep technical expertise in soft and continuum robotics with fluidic actuation, technologies we believe represent the future of surgery. These systems offer high precision and dexterity at any depth in the body, thanks to highly flexible transmission lines that can navigate multiple bends without performance loss. This is key to unlocking safer, scar-free endoluminal surgery for all patients.